Takeda Collaborates with Foundation Medicine for Lung Cancer CDx

Shots:

• The two companies collaborated for the development of Foundation Medicine’s tissue & blood-based CDx to be used with marketed and investigational treatments in Takeda’s late-stage lung cancer portfolio
• If approved, the CDx will be used to identify patients who may be eligible for mobocertinib for EGFR Exon20 insertion + mNSCLC and Alunbrig (brigatinib) for patients with TKI-naïve mNSCLC
• Under the agreement, Foundation Medicine will leverage its FoundationOne CDx and FoundationOne Liquid CDx for Takeda’s therapies. The US FDA’s approved CDx allow oncologists to identify patients who may be appropriate for FDA-approved targeted therapies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Progonos